Buckingham Research Starts Adient (ADNT) at Neutral
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Buckingham Research initiated coverage on Adient (NYSE: ADNT) (when issued) with a Neutral rating.
Shares of Adient closed at $0.03 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Seaport Global Securities Starts GCP Applied Technologies (GCP) at Buy
- Credit Suisse Reinstates CBS (CBS) at Outperform
- Wedbush Assumes PayPal (PYPL) at Outperform
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesBuckingham Research
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!